Thimerosal Allergy: The ACDS Non-Allergen of the Year & Vaccine Facts

In the United States, all routine pediatric vaccines — DTaP, hepatitis B, Hib, pneumococcal conjugate, IPV, MMR, varicella, rotavirus, HPV, and meningococcal — are thimerosal-free or contain only trace amounts since 2001. Some multi-dose influenza vaccine vials and certain tetanus toxoid/Td formulations still contain thimerosal as a preservative, but single-dose influenza vaccines are thimerosal-free and widely available. The FDA Modernization Act of 1997 initiated the review process, and the AAP/PHS joint statement of 1999 called for precautionary removal. If you want to avoid thimerosal entirely, request a single-dose influenza vaccine when getting your annual flu shot.

No. Multiple large-scale epidemiologic studies have thoroughly investigated and rejected a causal link between thimerosal-containing vaccines and autism spectrum disorder. The Institute of Medicine 2004 report concluded that the evidence favors rejection of a causal relationship. Parker et al. in Pediatrics 2004 conducted a systematic review reaching the same conclusion. Thompson et al. in the New England Journal of Medicine 2007 studied 1,047 children and found no adverse neuropsychological outcomes from thimerosal exposure. Price et al. in Pediatrics 2010 found no association in a case-control study of 256 cases and 752 controls. The Wakefield 1998 Lancet paper that seeded public concern was fraudulent, formally retracted in 2010, and the author was struck from the UK medical register.

Ethylmercury (from thimerosal) and methylmercury (from environmental contamination in fish) are chemically distinct compounds with vastly different pharmacokinetic profiles. Ethylmercury has a blood half-life of approximately 7 days and is excreted primarily through the gut. Methylmercury has a blood half-life of approximately 50 days and bioaccumulates in brain tissue. Burbacher et al. in Environmental Health Perspectives 2005 demonstrated that ethylmercury is cleared from the blood and brain much more rapidly than methylmercury and does not accumulate. Conflating the two mercury forms is scientifically incorrect.

The American Contact Dermatitis Society designated thimerosal as Contact Non-Allergen of the Year in 2002, a uniquely paradoxical title reflecting the disconnect between high patch-test positivity rates (5-15% in screening populations) and low clinical relevance (only about 17% of positive tests correspond to actual clinical disease). Belsito explained in the American Journal of Contact Dermatitis that despite widespread sensitization, most people with positive thimerosal patch tests have no identifiable dermatitis caused by thimerosal, and over 90% tolerate vaccine challenge without systemic reaction. The designation aimed to educate clinicians against over-interpreting positive patch tests as clinically meaningful allergy.

No. The CDC and ACIP explicitly state that contact hypersensitivity to thimerosal is NOT a contraindication to vaccination with a thimerosal-containing vaccine. This is based on evidence from Aberer et al. and Lee-Wong et al. showing that over 90% of patch-test-positive patients tolerate intramuscular vaccine challenge without systemic reaction. If you prefer to minimize thimerosal exposure, request single-dose, thimerosal-free vaccine formulations which are widely available for influenza and other vaccines. But refusing vaccination based solely on a positive thimerosal patch test is not medically supported and may put you at greater risk from vaccine-preventable diseases.

True IgE-mediated anaphylaxis to thimerosal itself is exceedingly rare — thimerosal contact allergy is a Type IV delayed hypersensitivity reaction, not an IgE-mediated immediate reaction. Vaccine anaphylaxis, when it occurs (approximately 1 per million doses), is typically caused by other vaccine components such as gelatin, egg proteins, or polyethylene glycol, not thimerosal. The distinction between Type IV contact allergy (delayed, localized skin reaction) and Type I IgE allergy (immediate systemic reaction) is critical for vaccination decision-making. If you have a history of genuine anaphylaxis following a thimerosal-containing product, consult an allergist for further evaluation.

Thimerosal was removed from US pediatric vaccines as a precautionary measure, not because evidence of harm was found. The FDA Modernization Act of 1997 mandated a review of all mercury-containing drugs. When the total calculated mercury exposure from the expanding pediatric vaccination schedule exceeded some environmental mercury guidelines (designed for methylmercury, not ethylmercury), the AAP and Public Health Service issued a 1999 joint statement recommending removal as a precautionary step to maintain public confidence. Subsequent large-scale epidemiologic studies confirmed no harm from the levels of ethylmercury in the previous vaccination schedule. The removal was a public confidence measure, not a safety-driven withdrawal.

Historically, thimerosal appeared in many products: contact lens cleaning and soaking solutions (notably Bausch & Lomb ReNu), topical antiseptics (Merthiolate — the familiar red antiseptic used for cuts and scrapes), ophthalmic drops, otic drops, nasal sprays, and some cosmetics. In current US practice, nearly all of these have been reformulated to remove thimerosal. The main remaining sources are some multi-dose influenza vaccine vials and certain tetanus toxoid/Td vials. Internationally, thimerosal is still used in multi-dose vaccine vials in developing countries where single-dose formulations are not cost-effective. If you have clinically relevant thimerosal allergy, have your pharmacist verify any new medications or eye drops.